ArticleEBioMedicine2026
Translating transcriptomics analysis into diagnostic workflows: clinical variant identification and interpretation in hypothesis-driven and hypothesis-free approaches.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite significant advancements in genetic diagnosis, there are still bottlenecks in DNA-level testing. Challenges to diagnosis include the inability to identify the causal variant, and the lack of functional evidence leading to an accumulation of variants of uncertain significance (VUS). Recently, there has been growing evidence demonstrating the diagnostic value of RNA sequencing (RNA-seq).
methodsThis diagnostic study implemented RNA-seq analysis of blood (and fibroblasts, if available) in 102 patients with genetically undiagnosed diseases. An outlier analysis for gene expression and splicing was adopted through a multi-modal machine learning algorithm (i.e., Detection of RNA Outliers Pipeline-DROP).
findingsOur analysis aided the interpretation of 22/102 (21.6%) patients through both hypothesis-driven (i.e., with a prior genetic candidate; n = 10) and hypothesis-free (i.e., without a prior genetic candidate; n = 12) approaches. Not only did this workflow aid genetic diagnosis (n = 12), but it also provided additional information to known findings (n = 4) and guided the discovery of unestablished disease mechanisms (n = 6).
interpretationThis study demonstrated the clinical and scientific value of blood transcriptomics through both hypothesis-driven and hypothesis-free approaches. We have proposed an initial framework for RNA-seq implementation into the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines using PVS1 (null variants) and PP4 (phenotypic specificity). However, other considerations are required, including further clarifications for thresholds, and detailed guidance on the incorporation of different aspects of RNA-seq results (e.g., degree of nonsense-mediated decay and completeness of splicing).
fundingThis study was supported by grants from the Society for the Relief of Disabled Children, the Health and Medical Research Fund (HMRF) and Commissioned Paediatric Research at HKCH under HMRF both by the Health Bureau, The Government of the Hong Kong Special Administrative Region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.